#	Pagina
attuale pagina	/open-h2020/projects/207159/index.html

Opendata, web and dolomites

3DCC

Ready-to-use 3D Cell Cultures for early de-risking in drug development

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

3DCC project word cloud

Explore the words cloud of the 3DCC project. It provides you a very rough idea of what is the project "3DCC" about.

standard advantages 96 unacceptable assays 345 manually 466 23 bcc latest cancer made big million largely customers progress market candidate report enriched stem broad clear clinical 3dcc trials niches programs toxicity seven drug ready solution 800 lack commodity cell 37 facilities culture supply industry cagr markets competitive media successfully 6 cultures 3d 120 thriving compounds integration pharma tissue populations effect biological models appears compatibility business usd expensive capitalizing pharmaceutical 10 disposable format eliminate buy sera reagents pipeline drugs establishes kits opportunity biopharmaceutical tailor efficacy stemtek enter fail 2016 spheroid csc global economies companies thanks profile company precisely strategy 2021 treatment plate

Project "3DCC" data sheet

The following table provides information about the project.

Coordinator	STEMTEK THERAPEUTICS SL Organization address address: KABI 612 LABORATORIO 17 ASTONDO BIDEA S/N PARQUE TECHNOLOGICO Y CIENTIFICO DE BIZKAIA city: DERIO postcode: 48160 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	https://www.stemtektherapeutics.com/en/cell2sphere-kit
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-12-01 to 2017-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STEMTEK THERAPEUTICS SL STEMTEK THERAPEUTICS SL Organization address address: KABI 612 LABORATORIO 17 ASTONDO BIDEA S/N PARQUE TECHNOLOGICO Y CIENTIFICO DE BIZKAIA city: DERIO postcode: 48160 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (DERIO)	coordinator	50˙000.00

Map

Project objective

StemTek is a global biopharmaceutical company with a clear stem cell focus in drug development for cancer treatment. Only about 10% of the candidate compounds progress successfully through clinical development. Many drugs fail during clinical trials, especially during phase III, which is the most expensive phase of clinical development, largely due to the lack of clinical efficacy and/or unacceptable toxicity.

StemTek is developing a solution to make cell based assays a commodity: easy to get, easy to buy, easy to use, and disposable, so we eliminate the need for large tissue culture facilities. This new solution is a ready-to-use 3D spheroid culture in standard 96 well plate format that allows customers to profile their pipeline of compounds for their effect on CSC populations using 3D culture models.

Thanks to the 3DCC, a business opportunity appears to develop a multi-million euro business capitalizing on the thriving interest from Pharma in finding novel biological testing systems based on 3D cell culture. Latest Markets&market report (2016) establishes that the global 3D cell culture market is expected to reach USD 1,345.2 M by 2021 from USD 466.8 M in 2016 at a CAGR of 23.6% (market growth). According to BCC research, from the seven different niches, “Reagents, media and sera” is precisely the most relevant (37.2 %). 3DCC objectives are: • To produce tailor made kits to improve compatibility with different drug development programs, leading to a broad range of applications. • To use all the competitive advantages of CSC enriched 3D spheroid cultures in ready to use standard 96 well plate format. • The large-scale production of ready to use kits to be able to enter/supply the pharmaceutical industry to achieve economies of scale, and go from current 800 kits/year (manually) up to 120.000 kits per year. • The integration of CSC testing into the drug development strategy of top 10 Big Pharma companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DCC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DCC" are provided by the European Opendata Portal: CORDIS opendata.